Restasis vs Izervay
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Restasis | US Izervay | |
|---|---|---|
| Generic name | cyclosporine ophthalmic emulsion | avacincaptad pegol |
| Drug class | Calcineurin Inhibitor (Eye Drop) | Complement C5 Inhibitor |
| Treats | Chronic dry eye | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Astellas Pharma |
| Year approved | 2003 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $100M | — |
| Common side effects | Burning sensation, Eye redness, Watery eyes, Blurred vision | Bleeding in the eye, Increased eye pressure, Floaters, Risk of eye infection |
Frequently asked questions
Is Restasis or Izervay better?
Neither is universally "better." Restasis (cyclosporine ophthalmic emulsion) and Izervay (avacincaptad pegol) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Restasis and Izervay?
Restasis is a Calcineurin Inhibitor (Eye Drop) made by AbbVie (Allergan), while Izervay is a Complement C5 Inhibitor made by Astellas Pharma. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Restasis has the larger estimated TV advertising budget of the two.